WSF1-IN-1 |
Catalog No.GC62477 |
경구 활성 WSF1 억제제인 WSF1-IN-1(화합물 136)은 HepG2 부모 및 HepG2 WFS1 KO 세포주에서 IC50 값이 0.33μM 및 >27μM인 WSF1(Wolfram 증후군) 관련 종양에 대한 연구에 사용할 수 있습니다. , 각각.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2379577-82-7
Sample solution is provided at 25 µL, 10mM.
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively[1].
WSF1-IN-1 (compound 136) exhibits IC50 values of >27 μM and 0.03 μM for Hek293 empty vector and Hek293 WFS1 over-expressor, respectively. WSF1-IN-1 (compound 136) exhibits IC50 values of 0.05 μM (Colo-205 Control shRNA), >9 μM (Colo-205 WSF1 shRNA), 0.08 μM (DU4415 Control shRNA), 6.1 μM (DU4415 WSF1 shRNA), 0.26 μM (HepG2 Control shRNA), 2.2 μM (HepG2 WSF1 shRNA) for cell valiablity, respectively[1].
WSF1-IN-1 (compound 136, 100 mpk qd, orally, 14 days) exhibits 106.65% tumor growth inhibition (TGI) in NSCLC patient derived xenograft OD33996 nu/nu mice[1].
[1]. Lauffer, David J, et al. Preparation of pyridine compass. for the treatment of cellular proliferative disorders. US 20190322673 A1.
Average Rating: 5
(Based on Reviews and 23 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *